Ashwagandha review reports lower symptom scores, with gaps in trial details
A meta-analysis examined stress, anxiety and depression in adults, but the abstract leaves uncertainty about who benefited and how the trials compared treatments.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The pooled trials reported lower stress, anxiety and depression scores with ashwagandha supplementation. However, the abstract does not identify control treatments, participant diagnoses or intervention lengths, which limits interpretation of those results. The authors also describe variation across studies and call for stronger trials before translating the findings into clinical recommendations.
The authors flag heterogeneity across trials. The abstract omits adverse-event findings and details needed to assess applicability to particular patients, so benefits and safety cannot be assessed fully from this record.
Understanding the reported scale
The analysis expresses results using standardized mean differences, a way of combining measurements across scales. These estimates cannot be read as percentage symptom reductions or as the proportion of participants who recovered.
Dose patterns need context
The authors found statistical relationships between dose and stress scores across studies. The abstract does not identify an optimal dose or duration, and these analyses do not establish that increasing the dose would improve an individual's outcome.
The original publication
Effects of ashwagandha (Withania somnifera) on mental health in adults: A systematic review and dose-response meta-analysis of randomized controlled trials.
Alsanie SA, Alhodieb FS, Askarpour M
Complement Ther Med · 2026
- PubMed ID
- 41644067
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.